Summary
Dr. Amit Kumar Tripathi, Ph.D., is a Post-Doctoral Research Associate at the University of North Texas Health Science Center, specializing in translational biomedical research. Since 2020, he has led studies on molecular biomarkers in cancer, focusing on designing bioactive peptides for cancer and antimicrobial applications. His groundbreaking work, published in the Journal of Biological Chemistry, introduces novel peptides that selectively target breast cancer cells while being non-toxic to normal cells. Dr. Tripathi's expertise spans antimicrobial research, cancer therapeutics, and advanced lab techniques, with a focus on creating inhibitors for proteins involved in cancer progression and metastasis.
At the University of North Texas Health Science Center in Fort Worth, Texas, Amit Kumar Tripathi, Ph.D., a distinguished Post-Doctoral Research Associate in Vishwanatha’s Research Lab, is making significant strides in translational biomedical research. Since September 2020, Dr. Tripathi has been leading innovative studies focusing on molecular biomarkers in cancer, with a particular emphasis on bio-active peptide design and its implications for both antimicrobial and anti-cancer applications.
Dr. Tripathi’s recent publication in the esteemed Journal of Biological Chemistry underscores a groundbreaking study on first-in-class peptide molecules designed to target specific MIEN1 cancer signaling pathways, for which no inhibitors have been identified previously. This pioneering research introduces peptides that exhibit selective cytotoxicity against breast cancer cells in a mouse model while demonstrating non-toxicity to normal cells and possessing a favorable pharmacokinetic profile. These findings provide a novel approach to understanding and potentially intervening in crucial cancer signaling pathways, offering new perspectives on cancer treatment.
In addition to his recent achievements, Dr. Tripathi has a distinguished background in antimicrobial peptide design, particularly concerning antimicrobial-to-inflammation studies. His expertise extends to crafting and synthesizing anti-cancer peptides as part of an innovative strategy aimed at targeting various cancer types. His research interests also encompass antimicrobial methodologies, biophysics, the use of animal models for studying inflammation, and the development of pharmaceutical agents.
Currently, as a Post-Doctoral Associate, Dr. Tripathi is dedicated to formulating inhibitors for proteins that play pivotal roles in tumor metastasis and cancer progression. His comprehensive expertise in advanced laboratory techniques including biochemical assays, cell culture, animal cell isolation, animal surgery, molecular biology, qPCR, ELISA, microscopy, and drug design drives his innovative approach to tackling complex biomedical challenges.
For those interested in potential collaborations or in learning more about this cutting-edge research, connecting with Dr. Tripathi offers an opportunity to engage with transformative developments in cancer therapeutics and beyond.
